KSD 101
Alternative Names: KSD-101Latest Information Update: 19 Apr 2024
At a glance
- Originator Kousai Bio
- Class Antineoplastics; Cancer vaccines; Cell therapies; Dendritic cell vaccines; Gene therapies; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Haematological malignancies
- Phase 0 Lymphoma; Nasopharyngeal cancer
Most Recent Events
- 19 Apr 2024 Kousai Bio in collaboration with Sun Yat-sen University plans a phase 0 trial for Nasopharyngeal cancer (Locally recurrent, Metastatic disease, Second-line therapy or greater) in China (SC) in May 2024(NCT06370026)
- 09 Dec 2023 Efficacy, immunogenicity and adverse event data from phase I trial in EBV-associated Haematologic Neoplasms presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 04 Dec 2023 Phase-0 for Nasopharyngeal cancer (Locally recurrent, Metastatic disease) in China (SC) (NCT06097793)